Ensysce Biosciences (NASDAQ:ENSC) released its 4Q2024 results that showed a good cash balance of $3.5 million due in large part to the financing activities management has undertaken which we’ve ...

Ensysce Biosciences (ENSC) has entered into definitive agreements, providing the Company with an aggregate gross proceeds of approximately $1.1 ...

Nasdaq Surges Over 1%; Best Buy Posts Upbeat Earnings ...

SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for ...

Short interest in Ensysce Biosciences Inc (NASDAQ:ENSC) decreased during the last reporting period, falling from 39.18K to 38.81K. This put 3.1% of the company's publicly available shares short.

Ivan Bajic (ibajic at ensc.sfu.ca) Office hours: Monday and Wednesday, 13:00-14:00 online (Zoom, see the link in course materials) Introduction to the theories of probability and random variables, and ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...